Cogstate (ASX:CGS) Risk Assessment


ASX:CGS Cogstate Ltd ASX:CGS
77 GF Score
Price A$2.74
GF Value A$2.10
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cogstate Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cogstate is: Low Risk: Strong fundamentals, worth long-term holding.

Cogstate  (ASX:CGS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cogstate Risk Assessment Related Terms

ASX:CGS vs VEEV, BTSG, TEM: Risk Assessment Comparison

For the Health Information Services subindustry, Cogstate's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cogstate Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cogstate's Risk Assessment falls into.


ASX:CGS
77GF Score
Cogstate Ltd ASX:CGS
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.74 is trading 30.5% above its estimated GF Value™ of A$2.10. GuruFocus considers Cogstate to be Modestly Overvalued.

Key valuation signals for ASX:CGS:

  • Risk Assessment:
  • GF Value™: A$2.10 vs. price of A$2.74 (30.5% above fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score

Get the complete analysis for ASX:CGS

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.74
Price
A$2.10
GF Value